| abstract |
Provided herein are methods of using certain biomarkers, such as gene sets ( e.g ., a leukemic stem cell (LSC) signature), in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancer ( e.g , lymphoma, multiple myeloma (MM), and leukemia, such as acute myeloid leukemia (AML)). Also provided herein are methods of treating diseases using the treatment compounds. |